AU2021249129B2 - Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase - Google Patents
Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinaseInfo
- Publication number
- AU2021249129B2 AU2021249129B2 AU2021249129A AU2021249129A AU2021249129B2 AU 2021249129 B2 AU2021249129 B2 AU 2021249129B2 AU 2021249129 A AU2021249129 A AU 2021249129A AU 2021249129 A AU2021249129 A AU 2021249129A AU 2021249129 B2 AU2021249129 B2 AU 2021249129B2
- Authority
- AU
- Australia
- Prior art keywords
- subject
- fenebrutinib
- acceptable salt
- pharmaceutically acceptable
- baseline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US63/005,095 | 2020-04-03 | ||
| US202063051767P | 2020-07-14 | 2020-07-14 | |
| US63/051,767 | 2020-07-14 | ||
| PCT/US2021/025301 WO2021202825A1 (en) | 2020-04-03 | 2021-04-01 | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021249129A1 AU2021249129A1 (en) | 2022-10-20 |
| AU2021249129B2 true AU2021249129B2 (en) | 2026-06-04 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021249129A Active AU2021249129B2 (en) | 2020-04-03 | 2021-04-01 | Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12605376B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4125906A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023520469A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220163986A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115916205A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021249129B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022019846A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3177390A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2022002699A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296990A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012310A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI907406B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021202825A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI899163B (zh) * | 2020-02-28 | 2025-10-01 | 美商建南德克公司 | 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法 |
| BR112023021235A2 (pt) | 2021-05-14 | 2023-12-12 | Loxo Oncology Inc | Formas cocristalinas de um inibidor da tirosina quinase de bruton |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
| WO2024238524A1 (en) * | 2023-05-16 | 2024-11-21 | Genentech, Inc. | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| PL4049660T3 (pl) | 2016-02-29 | 2025-06-09 | F. Hoffmann-La Roche Ag | Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona |
| CN107043366B (zh) | 2017-04-25 | 2020-05-26 | 中国药科大学 | 4-氨基嘧啶类化合物、其制备方法及医药用途 |
| EP3626239B1 (en) | 2017-05-18 | 2024-07-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Ezh2 inhibitor combined with btk inhibitor for treating tumor |
| US20210113568A1 (en) * | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
| JP2022500408A (ja) * | 2018-09-12 | 2022-01-04 | デノボ バイオファーマ エルエルシー | エンザスタウリンとbtkの阻害剤との組合せおよびその使用 |
| EP3914250A1 (en) | 2019-01-22 | 2021-12-01 | F. Hoffmann-La Roche AG | Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase |
| TWI899163B (zh) | 2020-02-28 | 2025-10-01 | 美商建南德克公司 | 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法 |
-
2021
- 2021-04-01 TW TW110112266A patent/TWI907406B/zh active
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en not_active Ceased
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 US US17/995,259 patent/US12605376B2/en active Active
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko active Pending
- 2021-04-01 AU AU2021249129A patent/AU2021249129B2/en active Active
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Non-Patent Citations (1)
| Title |
|---|
| National Center for Biotechnology Information. "PubChem Compound Summary for CID 86567195, Fenebrutinib" PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Fenebrutinib. * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022019846A2 (pt) | 2022-11-22 |
| TW202203925A (zh) | 2022-02-01 |
| IL296990A (en) | 2022-12-01 |
| JP2023520469A (ja) | 2023-05-17 |
| CN115916205A (zh) | 2023-04-04 |
| US12605376B2 (en) | 2026-04-21 |
| KR20220163986A (ko) | 2022-12-12 |
| TWI907406B (zh) | 2025-12-11 |
| EP4125906A1 (en) | 2023-02-08 |
| AU2021249129A1 (en) | 2022-10-20 |
| CL2022002699A1 (es) | 2023-03-31 |
| WO2021202825A1 (en) | 2021-10-07 |
| CA3177390A1 (en) | 2021-10-07 |
| US20230149395A1 (en) | 2023-05-18 |
| MX2022012310A (es) | 2022-10-27 |